Clinical Trials Logo

Filter by:
NCT ID: NCT05005130 Not yet recruiting - HIV Clinical Trials

Task-shifted Adaptation of the WHO-PEN Intervention to Address Cardio-metabolic Complications in People Living With HIV in Zambia

TASKPEN
Start date: August 2021
Phase: N/A
Study type: Interventional

This mixed-methods formative research study aims to adapt the WHO Package of Essential Noncommunicable Disease Interventions (WHO-PEN) approach for the Zambian public health system, and pilot test an adapted, streamlined, and task-shifted package of integrated HIV Noncommunicable Disease (NCD) services, collectively called "TASKPEN".

NCT ID: NCT04972903 Not yet recruiting - Tuberculosis Clinical Trials

Impact of Malnutrition on Pharmacokinetic or Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children

TB-Speed TB-PK
Start date: August 2021
Phase:
Study type: Observational

TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in TB-HIV co-infected children in Uganda and Zambia.

NCT ID: NCT04891250 Not yet recruiting - SARS-CoV-2 Clinical Trials

The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19

ZIT
Start date: October 2021
Phase: Phase 4
Study type: Interventional

The study aims to test whether Ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length of stay in ICU and transition probabilities to ICU (ventilator).

NCT ID: NCT04888377 Not yet recruiting - Clinical trials for Neurodevelopmental Abnormality

ASPIRIN: Neurodevelopmental Follow-up Trial

Start date: September 2021
Phase:
Study type: Observational

A total of 620 children will be enrolled in this study from six sites in sub-Saharan Africa, South Asia, and Latin America. Half of the children's mothers will have taken aspirin and half will have taken placebo. This will allow the researchers to compare results of the two groups of children and determine if children exposed antenatally to low dose aspirin will have scores on the Bayley Scales of Infant Development-III (BSID-III) examination at 36 months of life (+/-3months) that are not inferior to the child's peers who were not exposed (i.e., by no more than a margin of 4 points).

NCT ID: NCT04844255 Completed - Blood Pressure Clinical Trials

Acute Salt Sensitivity of Blood Pressure

AcuteSS
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

Dietary salt raises blood pressure in certain individuals immediately after ingestion (acute salt sensitivity; ASS) while not affecting others. It is hypothesized that ASS is a risk factor for hypertension. However, no thresholds or diagnostic guideline is available for ASS. This study is the first aim in the main study (HIPO CAP DITSH Study) aimed at determining the threshold or blood pressure cut-offs for ASS upon ingesting dietary salt.

NCT ID: NCT04839900 Recruiting - Malaria Clinical Trials

Proactive Community Case Management for Malaria in Zambia

ProACT
Start date: April 15, 2021
Phase: N/A
Study type: Interventional

To study if a proactive strategy of weekly household visits by community health workers (CHWs) to identify people with malaria symptoms, offer diagnostic testing, and treatment for those with positive tests in Chadiza District, Eastern Province, can decrease malaria incidence and prevalence compared to conventional community case management.

NCT ID: NCT04838587 Recruiting - Clinical trials for Escherichia Coli Diarrhea

An Epidemiological Surveillance Study to Determine the Incidence of ETEC in Children and Infants in Lusaka

ETEC-Surv
Start date: October 15, 2020
Phase:
Study type: Observational

Diarrhoea is the one of the top five leading causes of death among children below the age of five years, globally. It is estimated that one in ten deaths in children under five is attributed to diarrhoea. Enterotoxigenic E.coli (ETEC) is one of the major causative agents of moderate-to-severe (MSD) diarrhoea among children both globally and in Zambia. The overall aim of this study is to document the burden of ETEC associated diarrhoea in Zambian children under 3 years of age.

NCT ID: NCT04800055 Recruiting - Malaria Clinical Trials

Attractive Targeted Sugar Bait Phase III Trial in Zambia

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The trial will evaluate the efficacy of ATSB deployment plus universal coverage of a WHO core vector control (VC) interventions over two transmission seasons on a minimum 30% reduction in cohort clinical disease incidence, confirmed case incidence, and parasite prevalence, as compared with VC alone. Measurement of entomological outcomes, assessment of acceptability and barriers to uptake and consistent use of ATSB, safety and adverse event monitoring and estimation of the cost and cost-effectiveness of ATSB will also occur.

NCT ID: NCT04754386 Recruiting - HIV Testing Clinical Trials

Caregiver-Assisted Oral Fluid-based HIV Screening in Children: Zambia

Start date: February 8, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate the acceptability, feasibility and effectiveness of a caregiver-assisted oral fluid-based HIV test to screen children for HIV in Zambia. The results of this study are intended to support expanded access to HIV testing and treatment services for children, and to ensure that all newly diagnosed children are linked to clinical care.

NCT ID: NCT04738812 Not yet recruiting - Tuberculosis Clinical Trials

Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

DATURA
Start date: September 2021
Phase: Phase 3
Study type: Interventional

DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 cells/μL over 48 weeks: - Intensified TB treatment regimen: increased doses of rifampicin and isoniazid together with standard-dose of pyrazinamide and ethambutol for 8 weeks in addition to prednisone for 6 weeks and albendazole for 3 days - WHO standard TB treatment regimen. The continuation phase of TB treatment will be identical in the two arms: 4 months of rifampicin and isoniazid at standard doses.